In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Zacks.com on MSN22h
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on UpdatesIt was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Zacks.com on MSN21h
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
24/7 Wall St. on MSN9d
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street ExpertThis post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...
Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback